Kosan Biosciences
Kosan names its lead Hsp90 inhibitor compounds KOS-953 and KOS-1022
Published in Pharma Investments, Ventures and Law Weekly, September 24th, 2006
KOS-953 is named tanespimycin and KOS-1022 is named alvespimycin hydrochloride. The compound names have been adopted by the United States Adopted Names Council and the World Health Organization.
Tanespimycin is the most advanced Hsp90 inhibitor in clinical trials. The compound is in a phase Ib trial in combination with Velcade for multiple myeloma, and is in a phase I trial as a single agent in multiple myeloma. Tanespimycin is also being evaluated in a phase II combination trial with Herceptin for breast cancer, and in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- 4-Antibody
4-Antibody closes CHF 6 million series A financing, appoints Sijmen de Vries as CEO - Ablynx
Ablynx completes EUR 40 million series C financing - Adams Respiratory Therapeutics
Adams Respiratory Therapeutics reports 35% increase in net sales - Affymetrix
Affymetrix announces update regarding stock option grants - Arrowhead Research
Arrowhead names Paul McDonnel as VP, finance and accounting - Arrowhead Research
Arrowhead raises additional capital from institutional shareholders - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
